TEHRAN UNIVERSITY OF MEDICAL SCIENCES

A randomized, double-blind, phase III clinical trial (Aug 2019–Oct 2021) in Iran compared Xacrel (300 mg, then 600 mg every 24 weeks) to Ocrevus (same regimen) in MS patients. Primary outcome was ARR reduction equivalence at week 48. Secondary outcomes included disability progression, relapse-free patients, MRI lesion changes, and safety assessments. The study adhered to ethical and regulatory standards.

A network meta-analysis by Omid Kohandel Gargari, MD, found that pregabalin and topiramate, with or without vitamin D3, reduced migraine frequency in children and adolescents. Other treatments like flunarizine, levetiracetam, riboflavin, amitriptyline, and cinnarizine also showed potential but required more studies. Combination therapies, especially with vitamin D3, showed significant benefits, though no treatments significantly improved quality of life or reduced attack duration. Adverse events were highest with amitriptyline, topiramate, and valproate.